References
- FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer2010127122893291721351269
- NCCN Guidelines – Clinical Practice Guidelines in OncologyNon-small cell lung cancer Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdfAccessed May 16, 2012
- D’AddarioGFruhMReckMBaumannPKlepetkoWFelipEMetastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol2010215116119
- MountainCFThe international system for staging lung cancerSemin Surg Oncol200018210611510657912
- GoldstrawPCrowleyJChanskyKThe IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumoursJ Thorac Oncol20072870671417762336
- GazdarAFActivating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene20092812431
- RamalingamSBelaniCSystemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directionsOncologist200813151318263769
- SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
- BrodowiczTKrzakowskiMZwitterMCisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a Phase III trialLung Cancer200652215516316569462
- FidiasPMDakhilSRLyssAPPhase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancerJ Clin Oncol200927459159819075278
- European Medicines AgencyTarceva (erlotinib) – EU label and approval Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000618/WC500033994.pdfAccessed May 16, 2012
- US Food and Drug AdministrationTarceva (erlotinib) – FDA label and approval Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdfAccessed May 16, 2012
- CappuzzoFCiuleanuTStelmakhLErlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase 3 studyLancet Oncol201011652152920493771
- VergnenègreARayJChouaidCCross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancerClinicoecon Outcomes Res201241313722347803
- ShepherdFADanceyJRamlauRProspective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapyJ Clin Oncol200018102095210310811675
- ShepherdFARodriguesPJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
- HannaNShepherdFAFossellaFVRandomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapyJ Clin Oncol20042291589159715117980
- European Medicines AgencyAlimta (pemetrexed) – EU label and approval Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000564/WC500025611.pdfAccessed May 16, 2012
- CascianoRBischoffHNuijtenMMalangoneERayJMaintenance erlotinib versus pemetrexed for the treatment of non-small cell lung cancer: indirect comparison applying real-life outcomesProceedings of the International Society for Pharmacoeconomics and Outcomes Research 13th Annual European CongressNovember 6–9, 2010Prague, Czech Republic
- NuijtenMJde CastroCJChouaidCA cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancerLung Cancer201276346547122153602
- Ontario Health Technology Advisory CommitteeEpidermal growth factor receptor (EGFR) mutation testing for prediction of response to EGFR-targeting tyrosine kinase inhibitor (TKI) drugs in patients with advanced non-small-cell lung cancerPresentedat the Ontario Health Technology Advisory committeeAugust, 2010 Available at: http://www.health.gov.on.ca/english/providers/program/ohtac/tech/recommend/rec_EGFR_20101209.pdfAccessed May 16, 2012
- BradburyPATuDSeymourLEconomic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancerJ Natl Cancer Inst2010102529830620160168